VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma.

摘要: The effectiveness of anti-angiogenic therapy in glioblastoma (GBM) is probably the most controversial topic neuro-oncology. Results from recently completed clinical trials with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), are openly discordant1–3 and contrast impressive previous evidence.4 Furthermore, none these studies succeeded to establish predictive biomarkers for response which urgently needed.3 Thus, rethinking on rationale treatment GBM warranted. VEGF main regulator angiogenesis exists several isoforms different molecular weights biologic properties.5 Notably, bevacizumab binds all isoforms. We aimed test hypothesis that each tumor may synthesize given spectrum isoforms, sensitivity depend relative amount various